Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06126497 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating Safety and Efficacy of Ropanicant in MDD Patients
A Phase 2 study, sponsored by Suven Life Sciences Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT06126497 is a Phase 2 study that has completed, run by Suven Life Sciences Limited. The registered enrollment target is 41 participants.
The verdict
NCT06126497, a Phase 2 study, has completed, sponsored by Suven Life Sciences Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
This is an open-label, parallel-group study to evaluate the safety and efficacy of ropanicant in participants with moderate to severe Major Depressive Disorder (MDD).
Interventions
- DRUG Ropanicant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2024-02-05 |
| Est. Completion | 2024-07-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06126497
The ClinicalTrials.gov registry entry for NCT06126497 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Suven Life Sciences Limited, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ropanicant is the first listed.
NCT06126497 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06126497 about?
NCT06126497 is a clinical study titled "Study Evaluating Safety and Efficacy of Ropanicant in MDD Patients". This is an open-label, parallel-group study to evaluate the safety and efficacy of ropanicant in participants with moderate to severe Major Depressive Disorder (MDD).
What is the current status of trial NCT06126497?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2024-02-05. Estimated completion is 2024-07-19.
What interventions are being tested in trial NCT06126497?
The interventions under investigation include: Ropanicant (DRUG).
Who is sponsoring clinical trial NCT06126497?
This trial is sponsored by Suven Life Sciences Limited, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.